Business
CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), today announced an important update regarding its Caldolor® (ibuprofen) Injection. The product's permanent J-code, J1741, is now officially associated with a reimbursement price, providing healthcare providers with a CMS-covered, non-opioid option for managing pain and fever.
About this update from Cumberland Pharmaceuticals Inc.
[{"type":"text","content":"NASHVILLE, Tenn., Dec. 8, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), today announced an important update regarding its Caldolor® (ibuprofen) Injection. The product's permanent J-code, J1741, is now officially associated with a reimbursement price, providing healthcare providers with a CMS-covered, non-opioid option for managing pain and fever.","length":375,"tagName":"p"},{"type":"text","content":"As the nation continues to face an opioid crisis, non-opioid alternatives, like Caldolor, play a critical role in reducing reliance on opioid medications, supporting safer pain management strategies for patients. With the reimbursement price now linked to J1741, providers can access a CMS-covered, non-opioid pain management option and align treatment strategies with opioid-sparing initiatives.","length":396,"tagName":"p"},{"type":"text","content":"Caldolor J-Code Details: ","length":24,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Product: Caldolor® (ibuprofen) Injection","length":45,"tagName":"p"}]},{"val":[{"type":"text","content":"J-Code: J1741 – Injection, ibuprofen, 100 mg","length":44,"tagName":"p"}]},{"val":[{"type":"text","content":"Status: Now associated with reimbursement price","length":47,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":136,"olType":false},{"type":"text","content":""With Caldolor now linked to an established reimbursement price, healthcare providers have a reimbursable non-opioid alternative to help address pain management," said Cumberland Pharmaceuticals CEO A.J. Kazimi. "This update supports providers in making clinically appropriate decisions while contributing to efforts to reduce opioid exposure and reinforces our commitment to improving access to Caldolor and ensuring patients receive the pain management they need."","length":491,"tagName":"p"},{"type":"text","content":"Providers are encouraged to update their internal systems, billing teams, and reimbursement processes to reflect this change. For additional support with coding, coverage, or payment questions, please contact your Cumberland Pharmaceuticals representative or email [email protected].","length":295,"tagName":"p"},{"type":"text","content":"About Caldolor® (ibuprofen) Injection","length":42,"tagName":"p"},{"type":"text","co...